About: Synthetic Peptide Studies on the Severe Acute Respiratory Syndrome (SARS) Coronavirus Spike Glycoprotein: Perspective for SARS Vaccine Development

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Synthetic Peptide Studies on the Severe Acute Respiratory Syndrome (SARS) Coronavirus Spike Glycoprotein: Perspective for SARS Vaccine Development Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Synthetic Peptide Studies on the Severe Acute Respiratory Syndrome (SARS) Coronavirus Spike Glycoprotein: Perspective for SARS Vaccine Development
Creator	Ngai, Sai-Ming Tsai, Sau-Na Yang, Min Fung, Kwok-Pui Chan, Kay-Sheung Lo, Y Tam, Siu-Lun Choy, Wai-Yan Chu, Ida Miu-Ting Kwok-Wing, Stephen Lin, Shu-Guang Lin, Zhan-Yi Miu-Yee, Mary Ng, Kai-On Shan, Zhi-Xin Tsui, Waye, Wu, Yi-Long Zhong, Ming-Qi
source	Medline; PMC
abstract	Background: The S (spike) protein of the etiologic coronavirus (CoV) agent of severe acute respiratory syndrome (SARS) plays a central role in mediating viral infection via receptor binding and membrane fusion between the virion and the host cell. We focused on using synthetic peptides for developing antibodies against SARS-CoV, which aimed to block viral invasion by eliciting an immune response specific to the native SARS-CoV S protein. Methods: Six peptide sequences corresponding to the surface regions of SARS-CoV S protein were designed and investigated by use of combined bioinformatics and structural analysis. These synthetic peptides were used to immunize both rabbits and monkeys. Antisera collected 1 week after the second immunization were analyzed by ELISA and tested for antibody specificity against SARS-CoV by immunofluorescent confocal microscopy. Results: Four of our six synthetic peptides (S2, S3, S5, and S6) elicited SARS-CoV-specific antibodies, of which S5 (residues 788–820) and S6 (residues 1002–1030) exhibited immunogenic responses similar to those found in a parallel investigation using truncated recombinant protein analogs of the SARS-CoV S protein. This suggested that our S5 and S6 peptides may represent two minimum biologically active sequences of the immunogenic regions of the SARS-CoV S protein. Conclusions: Synthetic peptides can elicit specific antibodies to SARS-CoV. The study provides insights for the future development of SARS vaccine via the synthetic-peptide-based approach.
has issue date	2004-06-01(xsd:dateTime)
bibo:doi	10.1373/clinchem.2003.029801
bibo:pmid	15044316
has license	no-cc
sha1sum (hex)	29c8e6c9a49f04815754c6c29eec9f8bc7bb5070
schema:url	https://doi.org/10.1373/clinchem.2003.029801
resource representing a document's title	Synthetic Peptide Studies on the Severe Acute Respiratory Syndrome (SARS) Coronavirus Spike Glycoprotein: Perspective for SARS Vaccine Development
has PubMed Central identifier	PMC7108158
has PubMed identifier	15044316
schema:publication	Clin Chem
resource representing a document's body	covid:29c8e6c9a49f04815754c6c29eec9f8bc7bb5070#body_text
is schema:about of	named entity 'VIRAL' named entity 'IMMUNE RESPONSE' named entity 'VACCINE DEVELOPMENT' named entity 'SARS-COV' named entity 'SEVERE ACUTE RESPIRATORY SYNDROME' named entity 'CORONAVIRUS' named entity 'USING' named entity 'INVASION' named entity 'NATIVE' named entity 'VIRION' named entity 'DEVELOPING' named entity 'SARS VACCINE' named entity 'SYNTHETIC PEPTIDE' named entity 'PERSPECTIVE' named entity 'ANTIBODIES' named entity 'STUDIES' named entity 'FOCUSED' named entity 'ELICITING' named entity 'BLOCK' named entity 'SPECIFIC' named entity 'S PROTEIN' named entity 'HOST CELL' named entity 'SYNTHETIC PEPTIDES' covid:arg/29c8e6c9a49f04815754c6c29eec9f8bc7bb5070 named entity 'lyophilized' named entity 'antisera' named entity 'immune response' named entity 'SARS-CoV' named entity 'SARS' named entity 'Glycoprotein' named entity 'SARS' named entity 'Coronavirus' named entity 'three-dimensional structures' named entity 'kinetics' named entity 'Tween 20' named entity 'protein' named entity 'recombination' named entity 'host cell' named entity 'peptide' named entity 'viral RNA' named entity 'threonine' named entity 'carbodiimide' named entity 'kidney' named entity 'SARS-CoV' named entity 'Macaca fascicularis' named entity 'peptides' named entity 'molecular mass' named entity 'SARS-CoV' named entity 'protein' named entity 'genome' named entity 'N-glycosylation sites' named entity 'alkaline phosphatase' named entity 'N-hydroxysuccinimide' named entity 'SARS outbreak' named entity 'SARS-CoV' named entity 'genome sequence' named entity 'M. fascicularis' named entity 'molecular modeling' named entity 'peptide' named entity 'SARS-CoV' named entity 'serum' named entity 'peptide' named entity 'polymorphisms'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software